Inflarx Nv Stock Today
| IFRX Stock | USD 2.36 0.05 2.16% |
Performance14 of 100
| Odds Of DistressLess than 8
|
InflaRx NV is trading at 2.36 as of the 14th of December 2024; that is 2.16% up since the beginning of the trading day. The stock's open price was 2.31. InflaRx NV has only a 8 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 17th of June 2024 and ending today, the 14th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of November 2017 | Category Healthcare | Classification Health Care |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Fireman BV is traded on NASDAQ Exchange in the United States.. The company has 58.88 M outstanding shares of which 157.04 K shares are currently shorted by private and institutional investors with about 5.17 trading days to cover. More on InflaRx NV
Moving together with InflaRx Stock
| 0.86 | DYAI | Dyadic International | PairCorr |
| 0.86 | ESPR | Esperion Therapeutics | PairCorr |
| 0.75 | BMY | Bristol Myers Squibb | PairCorr |
Moving against InflaRx Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
InflaRx Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInflaRx NV can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand InflaRx NV's financial leverage. It provides some insight into what part of InflaRx NV's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
InflaRx NV (IFRX) is traded on NASDAQ Exchange in USA. It is located in Winzerlaer Str. 2, Jena, Germany, 07745 and employs 62 people. InflaRx NV is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 151 M. InflaRx NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 58.88 M outstanding shares of which 157.04 K shares are currently shorted by private and institutional investors with about 5.17 trading days to cover.
InflaRx NV currently holds about 23.68 M in cash with (37.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.54.
Check InflaRx NV Probability Of Bankruptcy
Ownership AllocationInflaRx NV has a total of 58.88 Million outstanding shares. InflaRx NV retains 7.34 (percent) of its outstanding shares held by insiders and 22.52 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check InflaRx Ownership Details
InflaRx Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Birchview Capital, Lp | 2024-09-30 | 50 K | |
| Geode Capital Management, Llc | 2024-09-30 | 36.2 K | |
| Northern Trust Corp | 2024-09-30 | 32.8 K | |
| Two Sigma Investments Llc | 2024-09-30 | 24 K | |
| Bnp Paribas Arbitrage, Sa | 2024-09-30 | 23.3 K | |
| Citadel Advisors Llc | 2024-09-30 | 22.9 K | |
| Pacifica Partners Inc | 2024-09-30 | 20.6 K | |
| Engineers Gate Manager Lp | 2024-09-30 | 19.8 K | |
| Schonfeld Strategic Advisors Llc | 2024-09-30 | 18.1 K | |
| Suvretta Capital Management, Llc | 2024-09-30 | 5.7 M | |
| 683 Capital Management Llc | 2024-09-30 | 2.1 M |
InflaRx NV Historical Income Statement
InflaRx Stock Against Markets
InflaRx NV Corporate Management
| Jan CFA | Head VP | Profile | |
| Thomas Taapken | Chief Officer | Profile | |
| Derval OCarroll | Senior Compliance | Profile | |
| Igor Orshanskiy | Senior Development | Profile | |
| Maria Habel | Head RD | Profile | |
| Christian Schmid | VP Counsel | Profile | |
| Kofi Boaten | Senior Supplies | Profile |
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.